Sulfanilamide copper(II) chelates with 2-[(2-hydroxyphenyl-imino)methyl]phenolom and 1-[(2-hydroxyphenylimino)-methyl]naphthalen-2-ol

2-[(2-Hydroxyphenylimino)methyl]phenol (H²L¹) and 1-[(2-hydroxyphenylimino)methyl]naphthalen-2-ol (H²L²) reacted with copper(II) acetate hydrate and sulfanilamide (Sf¹), sulfathiazole (Sf²), sulfaethidole (Sf³), sulfadiazine (Sf⁴), and sulfadimidine (Sf⁵) in ethanol to give mixed-ligand copper chelates with the composition Cu(Sf^1–5)(L^1–2) · n H₂O (n = 1, 2). All these complexes are monomeric. Salicylaldehyde imines (H₂L¹ and H₂L²) behave as doubly deprotonated tridentate O,N,O ligands, whereas sulfanilamides (Sf^1–5) are unidentate ligands. Thermolysis of the synthesized complexes includes dehydration at 70–90°C, followed by complete thermal decomposition (290–380°C). The complexes [Cu(Sf¹)(L¹)] · 2H₂O and [Cu(Sf³)(L¹)] · H₂O at a concentration of 10⁻⁴ M inhibited growth and reproduction of 100% of human myeloid leukemia cells (HL-60). The inhibitory effect was 90 and 75%, respectively, at a concentration of 10⁻⁵ M, whereas no antitumor activity was observed at a concentration of 10⁻⁶ M.